secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-08-04T11:52:06+00:00
Accession:  0001437749-26-025509
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed's neflamapimod gets UK Innovation Passport for DLB treatment
---------------------------------------------------------------------

- Innovation Passport awarded under UK ILAP for neflamapimod in dementia with Lewy bodies.
- Program designed to accelerate time to market and facilitate patient access in the UK.
- Provides coordinated guidance from MHRA, NHS, and HTA bodies (NICE, SMC, AWTTC).
- DLB is the second most common progressive dementia in older people in the UK; no approved treatment.
- CervoMed plans to use ILAP support to prepare for a Phase 3 trial of neflamapimod.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/0001437749-26-025509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926025509/crvo20260803_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer